Becton Dickinson Free Cash Flow 2012-2026 | BDX
Becton Dickinson annual/quarterly free cash flow history and growth rate from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Becton Dickinson free cash flow for the quarter ending March 31, 2026 was 0.00, a year-over-year.
- Becton Dickinson free cash flow for the twelve months ending March 31, 2026 was , a year-over-year.
- Becton Dickinson annual free cash flow for 2025 was $2.67B, a 14.4% decline from 2024.
- Becton Dickinson annual free cash flow for 2024 was $3.119B, a 47.4% increase from 2023.
- Becton Dickinson annual free cash flow for 2023 was $2.116B, a 41.26% increase from 2022.
| Becton Dickinson Annual Free Cash Flow | |
|---|---|
| 2025 | 2,670.00 |
| 2024 | 3,119.00 |
| 2023 | 2,116.00 |
| 2022 | 1,498.00 |
| 2021 | 2,932.00 |
| 2020 | 2,168.00 |
| 2019 | 2,373.00 |
| 2018 | 1,970.00 |
| 2017 | 1,823.00 |
| 2016 | 1,866.00 |
| 2015 | 1,134.00 |
| 2014 | 1,093.00 |
| 2013 | 1,129.00 |
| 2012 | 1,140.00 |
| 2011 | 1,039.00 |
| Becton Dickinson Quarterly Free Cash Flow | |
|---|---|
| 2025-12-31 | |
| 2025-09-30 | 2,670.00 |
| 2025-06-30 | 1,668.00 |
| 2025-03-31 | 623.00 |
| 2024-12-31 | 588.00 |
| 2024-09-30 | 3,119.00 |
| 2024-06-30 | 2,237.00 |
| 2024-03-31 | 1,119.00 |
| 2023-12-31 | 739.00 |
| 2023-09-30 | 2,116.00 |
| 2023-06-30 | 1,085.00 |
| 2023-03-31 | 195.00 |
| 2022-12-31 | 191.00 |
| 2022-09-30 | 1,498.00 |
| 2022-06-30 | 840.00 |
| 2022-03-31 | 415.00 |
| 2021-12-31 | 347.00 |
| 2021-09-30 | 2,932.00 |
| 2021-06-30 | 2,543.00 |
| 2021-03-31 | 2,222.00 |
| 2020-12-31 | 1,287.00 |
| 2020-09-30 | 2,168.00 |
| 2020-06-30 | 1,461.00 |
| 2020-03-31 | 801.00 |
| 2019-12-31 | 540.00 |
| 2019-09-30 | 2,373.00 |
| 2019-06-30 | 1,360.00 |
| 2019-03-31 | 665.00 |
| 2018-12-31 | 78.00 |
| 2018-09-30 | 1,970.00 |
| 2018-06-30 | 971.00 |
| 2018-03-31 | 626.00 |
| 2017-12-31 | 142.00 |
| 2017-09-30 | 1,823.00 |
| 2017-06-30 | 957.00 |
| 2017-03-31 | 768.00 |
| 2016-12-31 | 203.00 |
| 2016-09-30 | 1,866.00 |
| 2016-06-30 | 1,449.00 |
| 2016-03-31 | 762.00 |
| 2015-12-31 | 329.00 |
| 2015-09-30 | 1,134.00 |
| 2015-06-30 | 639.00 |
| 2015-03-31 | 245.00 |
| 2014-12-31 | 172.00 |
| 2014-09-30 | 1,093.00 |
| 2014-06-30 | 827.00 |
| 2014-03-31 | 523.00 |
| 2013-12-31 | 237.00 |
| 2013-09-30 | 1,129.00 |
| 2013-06-30 | 601.00 |
| 2013-03-31 | 314.00 |
| 2012-12-31 | 131.00 |
| 2012-09-30 | 1,140.00 |
| 2012-06-30 | 771.23 |
| 2012-03-31 | 333.06 |
| 2011-12-31 | 182.65 |
| 2011-09-30 | 1,039.00 |
| 2011-06-30 | 742.25 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $43.913B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |